Pretreatment L3 Skeletal Muscle Index Is Associated with Severe Oral Intake Impairment and a Longer Treatment-to-Discharge Interval in Patients with Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy.

Background/

Objectives

Pretreatment sarcopenia predicts adverse outcomes in head and neck squamous cell carcinoma (HNSCC). The conventional L3 skeletal muscle index (SMI) requires abdominal imaging, whereas the predictive value of the more accessible C3 muscle index for acute treatment-related complications remains uncertain. We compared pretreatment L3 SMI and the C3 index for identifying patients at risk of severe oral intake impairment, radiation interruption, and a longer treatment-to-discharge interval during definitive chemoradiotherapy.

Methods

This retrospective single-center study included 55 patients with HNSCC treated with 80 mg/m2 cisplatin every three weeks and 66 Gy intensity-modulated radiotherapy. Pretreatment computed tomography (CT) was analyzed using deep-learning-based automated segmentation. Firth-penalized logistic and multivariable linear regression were adjusted for age, sex, performance status, body mass index, and stage, with estimates standardized per 1-standard-deviation (SD) increase.

Results

L3 SMI was associated with severe oral intake impairment (adjusted odds ratio per SD, 0.248; 95% CI, 0.053-0.891) and the treatment-to-discharge interval (adjusted β, -6.23 days; 95% CI, -11.89 to -0.58); the C3 index was not associated with any outcome. The standardized coefficients differed for oral intake impairment (p = 0.014) but not for other outcomes. Each binary outcome comprised only 10 events.

Conclusions

L3 SMI was associated with nutritional vulnerability, whereas the fully automated C3 index was not; in an exploratory direct comparison, the two indices differed for severe oral intake impairment. These findings are hypothesis-generating and require confirmation in larger, multicenter cohorts.